Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Sofia Heigis M.Sc. | Chief Executive Officer | 2.47M | -- | 1980 |
| Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer | 4.82M | -- | 1972 |
| Prof. Rolf Larsson M.D., Ph.D. | Founder | -- | -- | -- |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder | -- | -- | -- |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder | -- | -- | -- |
| Dr. Kristina Luthman Ph.D. | Founder | -- | -- | -- |
| Prof. Hans Ehrsson M.D. | Founder | -- | -- | -- |
| Mr. Peter Nygren | Founder | -- | -- | 1959 |
| Mr. Henrik Bergentoft | Chief Financial Officer | -- | -- | 1974 |
| Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD | -- | -- | 1970 |
Oncopeptides AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 80
Description
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Corporate Governance
Upcoming Events
May 8, 2025 at 6:00 AM UTC
Oncopeptides AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available